Imbalances between proinflammatory and proresolving mediators can lead to chronic inflammatory diseases. The balance of arachidonic acid-derived mediators in leukocytes is thought to be achieved through intracellular localization of 5-lipoxygenase (5-LOX): nuclear 5-LOX favors the biosynthesis of proinflammatory leukotriene B 4 (LTB 4 ), whereas, in theory, cytoplasmic 5-LOX could favor the biosynthesis of proresolving lipoxin A 4 (LXA 4 ). This balance is shifted in favor of LXA 4 by resolvin D1 (RvD1), a specialized proresolving mediator derived from docosahexaenoic acid, but the mechanism is not known. Here we report a new pathway through which RvD1 promotes nuclear exclusion of 5-LOX and thereby suppresses LTB 4 and enhances LXA 4 in macrophages. RvD1, by activating its receptor formyl peptide receptor2/lipoxin A 4 receptor, suppresses cytosolic calcium and decreases activation of the calcium-sensitive kinase calcium-calmodulin-dependent protein kinase II (CaMKII). CaMKII inhibition suppresses activation P38 and mitogen-activated protein kinase-activated protein kinase 2 kinases, which reduces Ser271 phosphorylation of 5-LOX and shifts 5-LOX from the nucleus to the cytoplasm. As such, RvD1's ability to decrease nuclear 5-LOX and the LTB 4 :LXA 4 ratio in vitro and in vivo was mimicked by macrophages lacking CaMKII or expressing S271A-5-LOX. These findings provide mechanistic insight into how a specialized proresolving mediator from the docosahexaenoic acid pathway shifts the balance toward resolution in the arachidonic acid pathway. Knowledge of this mechanism may provide new strategies for promoting inflammation resolution in chronic inflammatory diseases.P ersistent inflammation and its failed resolution underlie the pathophysiology of prevalent human diseases, including cancer, diabetes, and atherosclerosis (1). Hence, uncovering mechanisms to suppress inflammation and enhance resolution is of immense interest (2-5). Resolution is orchestrated in part by specialized proresolving mediators (SPMs), including lipoxins, resolvins, protectins, and maresins (2), and by protein and peptide mediators (6). A common protective function of SPMs is their ability to limit excessive proinflammatory leukotriene formation without being immunosuppressive (2, 7). Specifically, resolvin D1 (RvD1) is protective in several disease models (8) and limits excessive leukotriene B 4 (LTB 4 ) production without compromising host defense (7, 9). However, the mechanism underlying these actions of RvD1 is not well understood.Arachidonic acid (AA) is first converted into 5-hydroperoxyeicosatetraenoicacid (5-HPETE) and then into leukotriene A 4 (LTA 4 ) by 5-lipoxygenase (5-LOX) (10, 11). Subsequent hydrolysis of LTA 4 by LTA 4 hydrolase yields LTB 4 (10, 11). During inflammation, 5-LOX is phosphorylated and translocates to the nuclear membrane, which favors the biosynthesis of LTB 4 (12-17). However, major gaps remain in our understanding of the relevance of this pathway to primary cells and animal models and how they are regulated by...